Originator / Branded Market Analysis
Cross-industry research covering Originator / Branded across 2 market reportsspanning Pharmaceuticals / Medical Devices — Regional Anesthesia, Pharmaceuticals.
Reports Covering Originator / Branded
Nerve Blocks Market to Reach USD 9.4 Billion by 2033 at 6.4% CAGR
Branded originator products in nerve blocks include liposomal bupivacaine (Exparel, Pacira BioSciences) and Naropeine (ropivacaine, AstraZeneca/generics in Europe). Originator share is structurally declining as extended-release formulation patents face challenge and clinical evidence on incremental efficacy over generic alternatives becomes more equivocal in prospective RCTs. The loss-of-exclusivity (LOE) waterfall for Exparel, with patent expirations clustered in the late 2020s, will materially reshape this segment's share by 2030 under our base case (Claritas model).
29%
Market Share
6.0%
Segment CAGR
Hospital Acquired Infection Control Market to Reach USD 41.6B by 2033 at 6.4% CAGR
Branded anti-infectives with active patent protection, including bezlotoxumab, novel beta-lactam/beta-lactamase inhibitor combinations, and pipeline echinocandins, command WAC premiums of 5–20x generic equivalents but face accelerating generic substitution following LOE. The IRA negotiation window applies to high-spend Medicare Part D biologics and could affect novel anti-infective biologics entering that threshold by 2030 (Claritas model).
33%
Market Share
5.4%
Segment CAGR